Literature DB >> 2474430

Dual inhibitory action of nedocromil sodium on antigen-induced inflammation.

S E Dahlén1, T Björck, M Kumlin, A Sydbom, J Raud, U Palmertz, L Franzén, R Grönneberg, P Hedqvist.   

Abstract

In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with either antigen or the individual inflammatory mediators, histamine and leukotriene B4. The findings thus indicate that nedocromil sodium has a dual anti-inflammatory action: inhibition of mediator secretion and antagonism of mediator action.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474430     DOI: 10.2165/00003495-198900371-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  17 in total

1.  Evidence indicating that leukotrienes C4, D4 and E4 are major mediators of contraction induced by anti-IgE in human bronchi.

Authors:  T Björck; S E Dahlén
Journal:  Agents Actions       Date:  1989-01

2.  Methylprednisolone acts at the endothelial cell level reducing inflammatory responses.

Authors:  J Björk; T Goldschmidt; G Smedegård; K E Arfors
Journal:  Acta Physiol Scand       Date:  1985-02

3.  Differences in the formation and metabolism of leukotrienes B4 and C4 in the human lung.

Authors:  M Kumlin; S E Dahlén; E Granström
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1987

Review 4.  The late phase of the immunoglobulin E-mediated reaction: a link between anaphylaxis and common allergic disease?

Authors:  G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1982-09       Impact factor: 10.793

5.  Intravital microscopic studies on acute mast cell-dependent inflammation.

Authors:  J Raud
Journal:  Acta Physiol Scand Suppl       Date:  1989

6.  Prostaglandin E2 prevents diclofenac-induced enhancement of histamine release and inflammation evoked by in vivo challenge with compound 48/80 in the hamster cheek pouch.

Authors:  J Raud; A Sydbom; S E Dahlén; P Hedqvist
Journal:  Agents Actions       Date:  1989-08

7.  Acute microvascular effects of PAF-acether, as studied by intravital microscopy.

Authors:  J Björk; G Smedegård
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

8.  Biological activities of lipoxin A include lung strip contraction and dilation of arterioles in vivo.

Authors:  S E Dahlén; J Raud; C N Serhan; J Björk; B Samuelsson
Journal:  Acta Physiol Scand       Date:  1987-08

9.  Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes.

Authors:  J Björk; P Hedqvist; K E Arfors
Journal:  Inflammation       Date:  1982-06       Impact factor: 4.092

10.  Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4.

Authors:  S E Dahlén; G Hansson; P Hedqvist; T Björck; E Granström; B Dahlén
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

View more
  4 in total

Review 1.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 2.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 3.  The Anti-allergic Cromones: Past, Present, and Future.

Authors:  Ajantha Sinniah; Samia Yazid; Roderick J Flower
Journal:  Front Pharmacol       Date:  2017-11-14       Impact factor: 5.810

4.  Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1.

Authors:  Samia Yazid; Egle Solito; Helen Christian; Simon McArthur; Nicolas Goulding; Roderick Flower
Journal:  Biochem Pharmacol       Date:  2009-03-24       Impact factor: 5.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.